Related Experiment Video
Updated: Aug 22, 2026
Studying Chronic Exposure of Mice to Ultraviolet B Radiation
Published on: August 19, 2025
Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series
1Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029, USA.
Background:
Mycosis fungoides, the most common form of cutaneous T-cell lymphoma, often presents as chronic eczematous or psoriasiform patches and plaques that can be resistant to a variety of single-agent treatment modalities, necessitating combination therapy.
Objective:
To evaluate the efficacy of combination therapy with bexarotene and psoralen plus ultraviolet A (PUVA) in treating patients with cutaneous T-cell lymphoma (CTCL) that recurred following monotherapy with multiple agents, including electron-beam irradiation, interferon, PUVA, and topical steroids. This was done by retrospective chart review.
Methods:
Retrospective chart review analysis of eight patients with CTCL ranging from stage Ia to IIb who failed multiple single-agent treatment regimens treated with low-dose oral bexarotene and PUVA combination therapy.
Results:
We noted an initial response in all eight patients and complete remission in five of the patients treated, with pruritus being the most common adverse event.
Conclusion:
In view of its good safety profile, combination therapy with bexarotene and PUVA may be considered for patients with treatment resistant CTCL refractory to monotherapy.
